EPAS1 and nonpapillary renal cell carcinoma: In phase I dose-escalation trial with advanced ccRCC,53,54 the first-generation HIF-2α inhibitor MK-3795 (PT2385) displayed a promising safety profile with no patients discontinuing therapy due to AEs and led to an ORR of 14% and a disease-control rate of 66% in 51 heavily pretreated patients.